MAM
VRCA icon

Meeder Asset Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Meeder Asset Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-415
Closed -$47K – 2650
2021
Q2 		$47K Buy
+415
New +$50.3K ﹤0.01% 1152
2020
Q4 		– Sell
-63
Closed -$5K – 2241
2020
Q3 		$5K Sell
63
-6
-9% -$492 ﹤0.01% 1601
2020
Q2 		$8K Sell
69
-323
-82% -$37.4K ﹤0.01% 1399
2020
Q1 		$42K Sell
392
-38
-9% -$5K ﹤0.01% 977
2019
Q4 		$69K Buy
+430
New +$63.5K ﹤0.01% 919

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Meeder Asset Management's VRCA Position: Q3 2021 in Review

Meeder Asset Management sold out of Verrica Pharmaceuticals (VRCA) in Q3 2021, closing a stake of 415 shares — an estimated $47K sold.

Meeder Asset Management first reported a position in VRCA in Q4 2019 and held it in 5 quarters. The position peaked at $69K in Q4 2019. 49 funds tracked by Wall St. Rank hold VRCA as of Q3 2021.

  • Meeder Asset Management reported no remaining Verrica Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Meeder Asset Management sold 415 Verrica Pharmaceuticals shares in Q3 2021, an estimated $47K.
  • Meeder Asset Management first reported a position in Verrica Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • Meeder Asset Management's Verrica Pharmaceuticals position peaked at $69K in Q4 2019.
  • 49 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2021.

Based on Meeder Asset Management's 13F filing for Q3 2021, filed 8 Nov 2021.